Portions of this Exhibit have been omitted pursuant to a request for
confidential treatment and the non-public information
has been filed with the SEC.
EXHIBIT 10.5
FIRST AMENDMENT TO SETTLEMENT AGREEMENT
THIS FIRST AMENDMENT TO SETTLEMENT AGREEMENT ("First Amendment"),
effective as of October 1, 2003, is made by and among Applera Corporation, a
Delaware corporation, acting through its Applied Biosystems Group ("AB"), Xxxxx
Xxxxxxxxx, of Newton, Massachusetts ("Xxxxxxxxx"), Lumigen, Inc., a Michigan
corporation ("Lumigen"), A. Xxxx Xxxxxx, of Grosse Point Park, Michigan
("Xxxxxx"), Xxxxx State University, a not for profit constitutional body
corporate organized under the laws of the State of Michigan ("WSU"), and
Diagnostic Products Corporation, a California corporation, ("DPC");
WHEREAS, Xxxxxxxxx, Lumigen, Xxxxxx, and WSU, along with Tropix, Inc.,
a Delaware corporation ("Tropix"), entered into a Settlement Agreement made
effective as of February 10, 1995 ("the Settlement Agreement"); and
WHEREAS, Tropix was later acquired by and thereafter merged into AB
(f/k/a The Xxxxxx-Xxxxx Corporation) and currently operates through Applera's
Applied Biosystems Group; and
WHEREAS, DPC purchases PPD and TB Enhancer (both as defined in the
Settlement Agreement) from Lumigen; and
WHEREAS, AB, Xxxxxxxxx, Lumigen, Xxxxxx and WSU, wish to amend the
Settlement Agreement as set forth in this First Amendment, and DPC, a guarantor
of Lumigen's payments to Tropix under the Settlement Agreement, wishes to be a
party to this First Amendment and to be bound by the covenants expressly set
forth herein;
NOW, THEREFORE, in consideration of the mutual undertakings set forth
herein, the parties agree as follows:
1. Unless the context of this First Amendment indicates otherwise,
capitalized terms used herein shall have the same meaning as defined in the
Settlement Agreement.
2. AB covenants and agrees, on its own behalf, and on behalf of its
affiliates, parent and subsidiary corporations, predecessors (specifically
including Tropix), successors and assigns, not to institute any suit, action or
proceeding in any court, state or federal, U.S. or foreign, or in any patent
office or tribunal, against Lumigen, or DPC, or any of their suppliers,
customers, licensees, affiliates, subsidiary or parent corporations,
predecessors, successors or assigns, arising out of DPC's use or sale or its
customers' use or sale of TB Enhancer purchased by DPC from Lumigen in
conjunction with PPD purchased by DPC from Lumigen as an element of human in
vitro diagnostics or veterinary diagnostics. DPC is no longer required to
purchase from AB, DPC's requirements for PPD and TB Enhancer for veterinary
diagnostic immunoassays.
3. DPC agrees to pay to AB within thirty (30) days after the end of
each calendar quarter starting January 1, 2003 and ending upon the last to
expire of the Assigned Patent Rights, as defined in the Settlement Agreement, a
royalty equal to * % of DPC's sales of Kits of medical diagnostic and veterinary
reagents which are used in conjunction with PPD and TB Enhancer. The term Kit
shall mean and include any product or commercial test which is manufactured by
or on behalf of DPC and sold or otherwise commercially exploited by or on behalf
of DPC and delivered for use with PPD and TB Enhancer as an element of human in
vitro diagnostics or veterinary diagnostics. A Kit normally contains active
buffers, antibody/antigen/DNA/peptide, conjugate and substrate (PPD and
enhancers). As a basis for determining the royalty rate set forth above, DPC has
provided its applicable reagent sales during calendar years 2000, 2001, and 2002
(see Exhibit 1).
4. Lumigen's obligation under Section 5.1 of the Settlement Agreement
to pay to AB a royalty equal to * percent ( * %) of Gross Revenues shall
continue; provided, however, that Lumigen shall exclude Gross Revenue derived
from the business of Lumigen with DPC as described in paragraph 2 above. This
exclusion shall continue in effect so long as DPC shall make the payments called
for in paragraph 3 above.
5. Except as modified by the provisions of this First Amendment, all
terms contained in the Settlement Agreement shall continue in full force and
effect.
IN WITNESS WHEREOF, the parties have caused this First Amendment to be
executed, corporate parties acting by and through their duly-authorized
officers, all on the day and date first above written.
Applera Corporation
through its Applied Biosystems Group
By /S/ Xxxxx Xxxxxx
-----------------------------------
Its Vice President
-----------------------------------
* Omitted pursuant to a request for
confidential treatment. This material has /S/ Xxxxx Xxxxxxxxx
been filed separately with the SEC. --------------------------------
Xxxxx Xxxxxxxxx
Lumigen, Inc.
By /S/ Xxxx X. Xxxxxxxx
-----------------------------
Its Vice President
------------------------
2
/S/ A. Xxxx Xxxxxx
--------------------------------
A. Xxxx Xxxxxx
Xxxxx State University
By /S/
-----------------------------
Its Vice President/General
Counsel
------------------------
Diagnostic Products Corporation
By /S/ Xxxxxxx Xxxxxxx
-----------------------------
Its President
------------------------
3
EXHIBIT 1
Lumigen Revenue with Diagnostic Products Corporation
November 7, 2002
Total Lumigen *% Royalty DPC *% Royalty
Revenue paid to Tropix Reagent as a % of DPC
Year with DPC from DPC business Sales Reagent Sales
---- -------- ----------------- ----- -------------
2000 * * 89,910,027 *%
2001 * * 117,772,135 *%
2002 (est) * * 144,734,132 *%
2003 (projection) * * 161,525,000 *%
4 year total * 513,941,294 *%
* Omitted pursuant to a request for confidential
treatment. This material has been filed
separately with the SEC
CERTAIN DEFINITIONS USED IN
FIRST AMENDMENT TO SETTLEMENT AGREEMENT
"PPD" shall mean 4-methoxy-4-(3-phosphatephenyl)spiro[1,2-dioxetane-3,
2-adamantane]disodium salt.
"TB Enhancer" shall mean polyvinylbenzyltributylphosphonium chloride.
"Assigned Patent Rights" shall mean the patents and patent applications
identified on Exhibit A attached hereto and any patents issuing from any such
patent applications, and any continuations, divisions, substitutions, reissues,
extensions and renewals of any of the foregoing.
EXHIBIT A
ASSIGNED PATENT RIGHTS
U.S. PATENTS
4,962,192
4,959,182
5,004,565
5,386,017
U.S. APPLICATIONS
06/887,139
07/023,649
07/265,890
07/677,097
08/020,302
08/021,022
08/186,461
08/262,564
08/339,085
FOREIGN PATENTS
Country Patent No.
------- ----------
Australia 603,736
Korea 69,259
Taiwan 46,563
FOREIGN PATENT APPLICATIONS
Country Filing Date Serial No.
------- ----------- ----------
Canada 5/13/87 537,003-5
Canada 9/21/93 616,729-2
Canada 5/31/89 601,376-7
Canada 12/20/89 2,006,222
Japan 6/11/91 236,758/91
Japan 6/11/91 236,759/91
Japan 7/24/89 191,247/89
Japan 6/29/93 187,042/93
Japan 12/21/89 502,424/89
*EPO 6/23/87 87108978.5
*EPO 11/25/93 93119049.0
*EPO 7/24/89 92109406.6
*EPO 8/21/92 92114339.2
*EPO 7/24/89 89113627.7
*EPO 12/21/89 89123690/3
China 7/27/89 89106249.1
China 7/27/89 93120975.7
India 9/6/89 454/MAS/89
India 7/6/93 457/MAS/93
* Includes (1) any national applications filed on the basis of this application,
(2) all rights to file any national application in any state designated in this
application, and (3) all national and European patents issued and to issue based
on this application.
